J&J To Put Johnson’s Bedtime Dispute To Rest With $5m Settlement
This article was originally published in The Rose Sheet
Executive Summary
Pending final approval in Illinois district court, Johnson & Johnson will pay $5m into a class action fund to settle litigation challenging “clinically proven” sleep claims attached to Johnson’s Baby Bedtime products.
You may also be interested in...
J&J Relaunches Johnson’s Baby Care As Greener, Gentler, With Fewer Ingredients
The overhaul in line with “modern parents’ preferences” could be what’s needed to rouse the sleepy brand and spur Consumer business growth.
J&J Highlights Plans For Reinventing Johnson’s Baby, Globalizing Aveeno
A planned restage of Johnson’s Baby will “completely reinvent the brand,” says Jorge Mesquita, global chairman of the J&J’s consumer division. Meanwhile, the firm is working to unfetter “captive” regional brands, expanding OGX and Aveeno across the globe while bringing Le Petit Marseillais to North America, among other growth initiatives.
Not Just J&J’s Problem: The Evolving Talc Litigation Landscape
Legal experts see cosmetic talc suits flaring along two tracks – either alleging the carcinogenicity of talc itself or linking cancer cases to asbestos-tainted talc sources. At least one attorney sees the latter as a potentially bigger threat to the cosmetics industry with the traditional pool of asbestos defendants drying up.